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Background: Many patients experience nausea and vomiting during chemotherapy treatment. Evidence demonstrates
that electroacupuncture is beneficial for controlling chemotherapy-induced nausea and vomiting (CINV). However, the
acupoint or matching acupoint with the best efficacy for controlling CINV still remains unidentified.
Methods/Design: This study consists of a randomized controlled trial (RCT) with four parallel arms: a control group and
three electroacupuncture groups (one with Neiguan (PC6), one with Zhongwan (CV12), and one with both PC6 and
CV12). The control group received standard antiemetic only, while the other three groups received electroacupuncture
stimulation with different acupoints besides the standard antiemetic. The intervention is done once daily from the first
day (day 1) to the fourth day (day 4) during chemotherapy treatment. The primary outcome measures include frequency
of nausea, vomiting and retching. The secondary outcome measures are the grade of constipation and diarrhea,
electrogastrogram, assessment of quality of life, assessment of anxiety and depression, and other adverse effects during
the chemotherapy. Assessments are scheduled from one day pre-chemotherapy (day 0) to the fifth day of chemotherapy
(day 5). Follow-ups are done from day 6 to day 21.
Discussion: The aim of this study is to evaluate the efficacy and safety of electro-acupuncture with different acupoints in
the management of CINV.
Trial registration: The register number of randomized controlled trial is NCT02195908. The date of registration was 21
July 2014.
Keywords: chemotherapy-induced nausea and vomiting, acupuncture, matching acupoint, randomized controlled trialIntroduction
Background
Despite the relevant progress achieved in the last 20
years, chemotherapy-induced nausea and vomiting
(CINV) is still one of the most distressing side effects of
cancer chemotherapy [1]. As 42 to 52% of patients ex-
perience nausea daily during regular treatment, nausea
continue to be a significant problem in chemotherapy
treatment [2]. The National Institutes of Health (NIH)* Correspondence: pangxingfang@163.com; guoyi_168@163.com
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unless otherwise stated.1997 Consensus Statement stated that “promising results
have emerged showing efficacy of acupuncture in adult
postoperative and chemotherapy nausea and vomiting”
[3]. Acupuncture has gained increasing popularity since
then as a choice of nonpharmacological adjunctive treat-
ment. Evidence-based medicine demonstrates that electroa-
cupuncture is beneficial towards chemotherapy-induced
acute vomiting, and The American Society of Clinical
Oncology recommends the usage of electoacupuncture for
managing nausea and vomiting in cancer patients [4].
However, no consensus exists on which set of compat-
ible acupoints is optimal, despite trials having been con-
ducted on acupoint matching. Some trials use singlehis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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ing acupoints. For example, Ezzo [5] found that stimu-
lating PC6 may be beneficial for various conditions
involving nausea and vomiting, and Shen [6] concluded
that electroacupuncture on PC6 (Neiguan) and ST36
(Zusanli) is more effective in controlling emesis than
minimal needling or antiemetic pharmacotherapy alone.
Hence the answer to the following question remains
unknown at present: Which compatible acupoint or acu-
points have better efficacy for CINV?
The aim of our study is to evaluate the different efficacies
and safety of electroacupuncture on a single point and
matching acupoints in the management of chemotherapy-
induced nausea and vomiting.
Hypotheses
According to the theory of Traditional Chinese Medicine
(TCM), acupoint compatibility can achieve a synergistic
effect. Our prior literature review found that clinically
matching acupoints are applied more often than a single
acupoint. The pairing of PC6 (Neiguan) with CV12
(Zhongwan) is one of the most commonly used match-
ing acupoints. Our hypothesis is that this pair helps to
reduce toxicity and enhance efficacy in the management
of chemotherapy-induced nausea and vomiting.
Objectives
Primary objective
Our primary objective in this trial is to assess the clinical
efficacy and safety of electroacupuncture on single point or
on double points in the management of chemotherapy-
induced nausea and vomiting (CINV).
Secondary objective
Secondary objective Our secondary objective is to as-
sess the quality of life, anxiety and depression of patients









The inclusion criteria include the following:
1. Be diagnosed by histopathology as a tumor patient
and accepts chemotherapy.
2. The scoring of Karnofsky (KPS) must be more
than 70.3. Patients of either gender, between 18 to 79 years
old inclusive.
4. Patients receiving chemotherapy as outpatients or
inpatients.
5. Patients receiving chemotherapy either for the first
time or undergoing multiple cycles will be taken
into the study only once.
6. Receive cis-platinum (cis-platinum ≥75 mg/m2) or
antharcycline combined chemotherapy (doxorubicin
≥40 mg/m2 or epirubicin ≥60 mg/m2)
7. Life expectancy of at least 6 months.
8. Willing to participate in the study and be randomly
allocated into one of the four study groups.
Exclusion criteria
Exclusion criteria include the following:
1. Receive radiotherapy concurrently with
chemotherapy.
2. Patients with gastrointestinal tumors.
3. Liver disease patients with serious complications,
or with serious hepatorenal abnormal function
(glutamic oxalacetic transaminase (AST),
glutamic-pyruvic transaminase (ALT), or total
bilirubin (TBIL) three times higher than normal or
blood urea nitrogen (BUN) or urine creatinine (Cr)
two times higher than normal).
4. Presence of cardiac pacemaker.
5. Active skin infection.
6. Nausea and/or vomiting as a result from opioids or
metabolic imbalance (electrolyte disturbances).
7. Patients unable to provide self-care or communicate,
or that have mental sickness,
8. Nausea and/or vomiting resulting from mechanical
risk factors (that is, intestinal obstruction).
9. Brain metastases or intracranial hypertension.
10.Women who are pregnant and or lactating.
Settings and data collection
All the patients are from the Tianjin Medical University
Cancer Institute and Hospital. Our trial started on 14
August 2014, and the first participant was recruited on
18 August 2014. The trial is planned to be completed in
one year [Figure 1].
Interventions
There are four arms in this randomized controlled trial.
The control group is supplied with antiemetic pharma-
ceutical, and the other three arms consist of antiemetic
drug and acupuncture.
Control group
The participants in the control group received standard
antiemetic alone. Standard antiemetic for all groups is
Figure 1 Flow diagram and schedule of enrollment, interventions, and assessments. Assessed for eligibility with eligibility criteria during
enrollment, the participants will be randomly divided among four arms: the control group is supplied with a pharmaceutical antiemetic, and the
other three arms consist of the antiemetic drug and one type of acupuncture (Neiguan (PC6) in one arm or Zhongwan (CV12) in another arm),
and the antiemetic drug and both types of acupuncture in the remaining arm. The treatment is scheduled to occur within 30 to 60 min before
chemotherapy infusion for 4 days. All assessments will be scheduled from the day before chemotherapy to the fifth day of chemotherapy, with
follow-up in the next 15 days, followed by data collection and analysis.
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Practice Guideline [7]. The 5-hydroxytryptamine-3
(5-HT3) antagonist (Ramosetron, Tropisetron) and
dexamethasone are administered before the chemo-
therapy treatment.
Experimental group I: single point PC6
Participants in experimental group I will receive electro-
acupuncture at the Neiguan (PC6) point. The location of
Neiguan (PC6) is on the anterior aspect of the forearm,
between the tendons of the palmaris longus and the
flexor carpi radialis, 2 B-cun proximal to the palmar
wrist crease [8]. After manipulation until a “de qi” sensa-
tion is achieved, the needle is connected to an electroa-
cupuncture apparatus. The positive pole is linked to theneedle, and the reference pole is secured approximately
1 cm proximal to the acupoint with a plaster. The fre-
quency used is 2/10 Hz, and the intensity of stimulation
is adjusted according to the patient’s tolerance, with the
electric current set at less than 10 mA. The procedure
lasts for 30 min. The treatment is scheduled to occur in
the 30 to 60 min before chemotherapy infusion for 4
days.
Experimental group II: single point CV12
The experimental group II will receive electroacupun-
ture at another single point, Zhongwan (CV12). The lo-
cation of Zhongwan (CV12) is on the upper abdomen, 4
B-cun superior to the center of the umbilicus, on the an-
terior median line [8]. After manipulation until a “de qi”
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troacupuncture apparatus. The positive pole is linked to
the needle, and the reference pole is secured approxi-
mately 1 cm proximal to the acupoint with a plaster.
The frequency used is 2/10 Hz, and the intensity of
stimulation is adjusted according to the patient’s toler-
ance, with the electric current set at less than 10 mA.
The procedure lasts for 30 min. The treatment is sched-
uled to occur in the 30 to 60 min before chemotherapy
infusion for 4 days.
Experimental group III: matching points PC6 plus CV12
The experimental group III will receive electroacupuncture
at both Neiguan point (PC6) and Zhongwan point (CV12).
After manipulation until a “de qi” sensation is achieved, the
needle is connected to an electroacupuncture apparatus.
The positive pole is linked to the needle, and the reference
pole is secured approximately one cm in the proximity of
the acupoint with a plaster. The frequency used is 2/10 Hz,
and the intensity of stimulation is adjusted according to the
patient’s tolerance, with the electric current set at less than
10 mA. The procedure lasts for 30 min. The treatment is
scheduled to occur in the 30 min to 60 min before chemo-
therapy infusion for 4 days.
Outcomes
Primary outcome
The primary outcomes are as follows:
1. The frequency of nausea and vomiting
Total nausea and vomiting episodes per person
over the 6-day study period will be recorded.
The frequency of nausea and vomiting is the
measurement with the most value for evaluation.
2. The grading of nausea and vomiting
The Common Terminology Criteria for Adverse
Events Version 4.0 [9] will be used to grade the
nausea and vomiting.
3. Rhodes Index of Nausea, Vomiting and Retching
The Rhodes Index of Nausea, Vomiting and
Retching [10], an eight-item validated scale,
will be used to measure the nausea and vomiting
experience, incidence and severity.
Secondary outcome measures
Secondary outcome measures include the following:
1. The grading of constipation and diarrhea
The Common Terminology Criteria for Adverse
Events Version 4.0 [9] will be used to evaluate the
grading of constipation and diarrhea.
2. Electrogastrogram
Electrogastrogram will be monitored to get the
information of gastrointestinal motility.3. The assessment of quality of life
The Functional Assessment of Cancer Therapy -
General (FACT-G) [11] will be applied to assess
the quality of life.
4. The assessment of anxiety and depression
The Hospital Anxiety and Depression Scale [12]
is a scale assessing anxiety with seven items and
depression with a further seven items.
5. Other adverse effects during the chemotherapy
Other adverse effects during the chemotherapy,
mainly including constipation and diarrhea, will be
assessed by The Common Terminology Criteria
for Adverse Events Version 4.0 [9].Safety
Any adverse reactions of patient will be recorded in the
case report form (CRF), including swelling, pain, bruise
at the sites of needle insertion, or discomfort, palpita-
tion, dizziness, etcetera after acupuncture.Participant timeline
The enrollment will be done before the day of chemo-
therapy on day zero. The electroacupuncture interven-
tion will be given once daily from day one to day four.
All assessments will be scheduled from day zero to day
five (see Table 1).Sample size
Sample size calculation has been based on the result of a
trial by Shen J [6] and the recommendation of acupunc-
ture specialists in China. The mean value of emesis
number in the Neiguan group is 12.5, the standard devi-
ation is 1.5, and the mean value of emesis number in
Neiguan plus Zhongwan group is 11, the standard devi-
ation is 1.5. To detect a significant difference between
any two groups with a power of 90% and type I error of
5%, the calculated number of patients is 132. Consider-
ing a 20% drop-out rate, the total sample size needs 160
patients.Allocation and sequence generation
The allocation sequence will be generated by center
computer. When the participants voluntarily join this
study with informed consents, the practitioner will open
the webite (http://iwrs.tice.com.cn/) and evaluate the in-
clusion and exclusion criteria. If they are accorded with
the inclusion criteria, the computer will generate a ran-
dom number and show which group the participant
should be in, and the practitioner will assign the partici-
pant to that intervention. The evaluator is blind to
which intervention the participant accepts.
Table 1 The schedule of enrollment, interventions, and assessments
Study Period
Enrollment Allocation Post-allocation closeout







Experimental group I × × × ×
Experimental group II × × × ×
Experimental group III × × × ×
Assessments:
baseline variables × ×
The frequency of nausea and vomiting × × × × × × ×
The grading of nausea and vomiting × × × × × × ×
Rhodes Index of nausea, vomiting and retching × × × × × × ×
the grading of constipation and diarrhea × × × × × ×
electrogastrogram × × ×
the assessment of quality of life × × ×
the assessment of anxiety and depression × × ×
other adverse effect during the chemotherapy × ×
the adverse effects of acupuncture × × × ×
t1, the day before the chemotherapy; t1-t5, the first day to the fifth day of chemotherapy; t6, the 21st day of chemotherapy.
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The computer-generated randomization is performed
remotely by the Evidence-Based Medicine Center in
Tianjin on the website of http://iwrs.tice.com.cn/.
Blinding
The evaluator and the statistician are blinded; neither
knows which intervention a participant accepts.
Statistical methods
Categorical data will be analyzed with the McNemar chi-
square test. We will use analysis of variance (ANOVA) to
analyze continuous data. If the data trends over time and
over time by treatment interactions, we will choose a
repeated-measures analysis of variance (ANOVA). A P
value less than 0.05 is regarded as statistically significant.
Quality control
All researchers will be required to undergo special train-
ing, including trial design, patient inclusion and exclu-
sion criteria, and on filling in the CRF. The practitioners
have all majored in acupuncture, have an acupuncture
degree, and are qualified doctors of Tradition Chinese
Medicine. All will have been trained in the standardoperating procedure of electroacupuncture. The moni-
tors will check all the case report forms. The reasons of
drop-outs and withdrawals during the study will be fully
recorded.Ethics
Written informed consent will be obtained from each
participant. This study is approved by Medical Ethics
Committee-Tianjin University of Traditional Chinese
Medicine. The approval number is TJUTCM-EC20140004.Discussion
Nausea and vomiting is one of the most common side
effects of chemotherapy [13]. Clinical evidence has
shown that acupoint stimulation has a certain effect on
chemotherapy-induced nausea and vomiting. However,
with different interventions used, different results are
obtained. Electroacupuncture is effective, and acupres-
sure is protective, while transcutaneous electrical stimu-
lation is ineffective [14]. The effects with the same
interventions but different acupoints are different. The
objective was to compare acupuncture effects of different
acupoint combinations; therefore, there are only a blank
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acupoint group, without a sham acupuncture group.
With respect to clinical quality control, the manipula-
tors, estimators and statisticians worked independently
to reduce the adverse impacts of artificial factors on
data. Although it cannot blind patients or researchers,
the estimator and statisticians are unclear about sectio-
nalization. All researchers received pre-work training,
and various operation management regulations were for-
mulated to guarantee the consistency of the operation
process and evaluation process. A third party has been
invited to manage the data independently and design a
central randomization system to minimize bias and
enhance clinical research quality.
Trial status
The trial is currently recruiting patients.
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